Drug Patents owned by Purdue Pharma Lp

1. Drug name - ADHANSIA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Oct, 2035

(13 years from now)

US10722473 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder Nov, 2038

(16 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
35MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
45MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
55MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
70MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
85MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

2. Drug name - HYSINGLA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675610 PURDUE PHARMA LP Abuse-proofed dosage form Jun, 2023

(8 months from now)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form Jun, 2023

(8 months from now)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9095614 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9095615 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9775809 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9486412 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9545380 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9084816 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492390 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9486413 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9572779 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

US8808740 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

US9861584 PURDUE PHARMA LP Tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

US9872837 PURDUE PHARMA LP Tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

US9750703 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms Dec, 2031

(9 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE;ORAL Prescription
60MG TABLET, EXTENDED RELEASE;ORAL Prescription
80MG TABLET, EXTENDED RELEASE;ORAL Prescription
100MG TABLET, EXTENDED RELEASE;ORAL Prescription
120MG TABLET, EXTENDED RELEASE;ORAL Prescription

3. Drug name - OXYCONTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10696684 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

US10407434 PURDUE PHARMA LP Process for preparing oxycodone compositions
Mar, 2025

(2 years from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(2 years from now)

US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

CN102127086B PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102887903B PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN1960994B PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN101812065A PURDUE PHARMA LP A Method For Preparing Oxycodone Hydrochloride Composition With Less Than 25Ppm Of 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102887903A PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102838607A PURDUE PHARMA LP Method For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm Of 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102838607B PURDUE PHARMA LP Preparation Contains Less Than 25 Ppm Of 14-Hydroxide Can Be Oxycodone Method By Hydrochloric Acid
Mar, 2025

(2 years from now)

CN101812065B PURDUE PHARMA LP Contains Less Than 25 Ppm Ppm Of 14-Hydroxymethyl Codeine To Oxycodone Hydrochloride Ketone Can Be Ketone
Mar, 2025

(2 years from now)

CN102127086A PURDUE PHARMA LP Method For Preparing Pancodine Composition Containing Less Than 25 Ppm Of 14-Oxycodone
Mar, 2025

(2 years from now)

CN1960994A PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2305683B1 PURDUE PHARMA LP Pharmaceutical Dosage Form Comprising Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2305683A1 PURDUE PHARMA LP Pharmaceutical Dosage Form Comprising Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2319846A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2426132A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Compositions Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2316837B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151B2 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2426132B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Compositions Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151A4 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2316837A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2305683B8 PURDUE PHARMA LP Pharmaceutical Dosage Form Comprising Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2319846B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675610 PURDUE PHARMA LP Abuse-proofed dosage form Jun, 2023

(8 months from now)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form Jun, 2023

(8 months from now)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US10675278 PURDUE PHARMA LP Crush resistant delayed-release dosage forms Nov, 2023

(1 year, 1 month from now)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form Nov, 2023

(1 year, 1 month from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492392 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9775808 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US8894988 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US8808741 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492393 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US8894987 PURDUE PHARMA LP Tamper resistant dosage forms Mar, 2030

(7 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, EXTENDED RELEASE;ORAL Prescription
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
20MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE;ORAL Prescription
60MG TABLET, EXTENDED RELEASE;ORAL Prescription
80MG TABLET, EXTENDED RELEASE;ORAL Prescription

4. Drug name - TARGINIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(2 years from now)

CN102127086B PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102887903B PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN1960994B PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN101812065A PURDUE PHARMA LP A Method For Preparing Oxycodone Hydrochloride Composition With Less Than 25Ppm Of 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102887903A PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102838607A PURDUE PHARMA LP Method For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm Of 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102838607B PURDUE PHARMA LP Preparation Contains Less Than 25 Ppm Of 14-Hydroxide Can Be Oxycodone Method By Hydrochloric Acid
Mar, 2025

(2 years from now)

CN101812065B PURDUE PHARMA LP Contains Less Than 25 Ppm Ppm Of 14-Hydroxymethyl Codeine To Oxycodone Hydrochloride Ketone Can Be Ketone
Mar, 2025

(2 years from now)

CN102127086A PURDUE PHARMA LP Method For Preparing Pancodine Composition Containing Less Than 25 Ppm Of 14-Oxycodone
Mar, 2025

(2 years from now)

CN1960994A PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2305683B1 PURDUE PHARMA LP Pharmaceutical Dosage Form Comprising Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2305683A1 PURDUE PHARMA LP Pharmaceutical Dosage Form Comprising Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2319846A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2426132A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Compositions Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2316837B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151B2 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2426132B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Compositions Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151A4 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2316837A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2305683B8 PURDUE PHARMA LP Pharmaceutical Dosage Form Comprising Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2319846B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846090 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds Apr, 2023

(5 months from now)

US8846091 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds Apr, 2023

(5 months from now)

US9907793 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone Apr, 2023

(5 months from now)

US9555000 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone Apr, 2023

(5 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;10MG TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG;20MG TABLET, EXTENDED RELEASE;ORAL Discontinued
20MG;40MG TABLET, EXTENDED RELEASE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.